Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.

Wang X, Li Y, Yan X.

Biomed Res Int. 2016;2016:6848902. doi: 10.1155/2016/6848902. Epub 2016 Feb 1. Review.

2.

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis.

Lyu WW, Zhao QC, Song DH, Zhang JJ, Ding ZX, Li BY, Wei CM.

Chin Med J (Engl). 2016 5th Feb;129(3):320-325. doi: 10.4103/0366-6999.174497.

3.

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.

Bonomo L, Lue J, Jagannath S, Chari A.

Cancer Med. 2016 Mar;5(3):500-5. doi: 10.1002/cam4.620. Epub 2016 Jan 22.

4.

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.

Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T.

Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11.

5.

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.

Yang WC, Lin SF.

Biomed Res Int. 2015;2015:341430. doi: 10.1155/2015/341430. Epub 2015 Nov 16. Review.

6.

Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.

Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M.

PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. eCollection 2015.

7.

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.

Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV.

Blood Cancer J. 2015 Mar 20;5:e294. doi: 10.1038/bcj.2015.23. No abstract available.

8.

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T.

Haematologica. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121. Epub 2015 Mar 13.

9.

Tretatment approach of nontransplant patients with multiple myeloma.

Krstevska SB, Sotirova T, Balkanov T, Genadieva-Stavric S.

Mater Sociomed. 2014 Oct;26(5):348-51. doi: 10.5455/msm.2014.26.348-351. Epub 2014 Oct 29. Review.

10.

Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Ria R, Reale A, Vacca A.

World J Methodol. 2014 Jun 26;4(2):73-90. doi: 10.5662/wjm.v4.i2.73. eCollection 2014 Jun 26. Review.

11.

Therapeutic advancements in multiple myeloma.

Gozzetti A, Candi V, Papini G, Bocchia M.

Front Oncol. 2014 Sep 4;4:241. doi: 10.3389/fonc.2014.00241. eCollection 2014. Review.

12.

Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.

Palumbo A, Palladino C.

Ther Adv Drug Saf. 2012 Oct;3(5):255-66. doi: 10.1177/2042098612452291. Review.

13.

Multiple myeloma in the older adult: better prospects, more challenges.

Wildes TM, Rosko A, Tuchman SA.

J Clin Oncol. 2014 Aug 20;32(24):2531-40. Review.

14.

Older patients with myeloma derive similar benefit from autologous transplantation.

Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803. doi: 10.1016/j.bbmt.2014.07.013. Epub 2014 Jul 18.

15.

Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.

Petrucci MT, Finsinger P, Chisini M, Gentilini F.

Patient Prefer Adherence. 2014 Jul 4;8:939-46. doi: 10.2147/PPA.S38142. eCollection 2014. Review.

16.

Age and aging in blood disorders: multiple myeloma.

Zweegman S, Palumbo A, Bringhen S, Sonneveld P.

Haematologica. 2014 Jul;99(7):1133-7. doi: 10.3324/haematol.2014.110296. No abstract available.

17.

Multiple myeloma in the very old: an IASIA conference report.

Tuchman SA, Shapiro GR, Ershler WB, Badros A, Cohen HJ, Dispenzieri A, Flores IQ, Kanapuru B, Jurivich D, Longo DL, Nourbakhsh A, Palumbo A, Walston J, Yates JW.

J Natl Cancer Inst. 2014 Apr 3;106(5). pii: dju067. doi: 10.1093/jnci/dju067.

18.

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network.

Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.

19.

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ.

J Clin Oncol. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. Epub 2014 Jan 13. Review.

20.

Current approaches to the initial treatment of symptomatic multiple myeloma.

Jasielec JK, Jakubowiak AJ.

Int J Hematol Oncol. 2013 Feb;2(1). doi: 10.2217/ijh.13.3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk